CE InformationDownload MaterialsCourse Progress
  • Access Webinar
  • Evaluation
  • Certificate
Evaluation

Management of Recurrent C. difficile Infection in Patients with IBD: Updates in An Era of Live Biotherapeutic Products

Evaluation

HMP Education would appreciate your feedback on the quality and impact of this activity.

Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little).

To what extent are you able to better achieve each of the following learning objectives?

Describe the burden of recurrent CDI in patients with IBD and the role of gut dysbiosis in recurrent CDI pathogenesis
Assess treatment challenges associated with recurrent CDI in the context of IBD
Evaluate newer and emerging non-antibiotic therapies for CDI treatment, including recently approved LBPs

Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor).

Jessica R. Allegretti, MD, MPH, FACG, AGAF
Jordan E. Axelrad, MD, MPH
Benjamin Cohen, MD, MAS, AGAF

Please rate the following components relating to this activity:

Content
Relevance to your practice 
Educational format 
Audience-participation portions (eg., Q&A, polling, pre/post-testing) 
Resources and/or other materials supporting the activity
Overall

Therapeutic recommendations presented in this activity did not encourage inappropriate or excessive use of products/devices.
How many patients do you encounter with C. diff on a weekly basis?

Do you feel like there were any new data presented?

Did you learn anything new?

Did you gain confidence on the new information?

Did this program include opportunities to learn as a part of a healthcare team?
Compared to patients without IBD, patients with IBD are _____ more likely to experience CDI recurrence.
Overlapping symptoms can complicate rCDI diagnosis among patients with IBD. Which of the following is a recommended initial test to increase the accuracy of a diagnosis of active CDI?
Data from the PUNCH CD3 trial demonstrated that treatment with fecal microbiota, live-jslm (previously RBX2660), resulted in a ____ success rate compared to placebo.
Data from the ESCOPOR IV phase 3 open-label study demonstrated that only 8.7% of patients treated with ______ experienced recurrence up to 8 weeks.
How confident are you now in your ability to utilize novel live biotherapeutic products (LBPs) for rCDI treatment among IBD patients when appropriate?

Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific.
What challenges or barriers outside of your control may prevent you from changing your practice?
255 characters max

The information presented in this activity did not serve to advance a proprietary interest of any commercial entity.
Based on my participation in this activity, I anticipate I will more often (select all that apply):